Epirubicin and Celecoxib in Treating Patients With Hepatocellular Carcinoma
Completed · Phase 1/Phase 2
Conditions studied: Liver Cancer
In brief
RATIONALE: Celecoxib may stop the growth of tumor cells by stopping blood flow to the tumor. Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. Combining celecoxib with epirubicin may kill more tumor cells. PURPOSE: This phase I/II trial is studying the side effects and best dose of epirubicin when given together with celecoxib and to see how well it works in treating patients with hepatocellular carcinoma (liver cancer).
Key facts
- Study ID
- NCT00057980
- Run by
- Northwestern University
- People needed
- 8
- Starts
- 2002-10-01
- Expected to finish
- 2007-02-01
- Last updated by the study team
- 2012-06-11
Who can join
Age: 18 and older. Sex: any. Healthy volunteers: not accepted.
Where it is running
- Robert H. Lurie Comprehensive Cancer Center at Northwestern University — Chicago, Illinois, United States
Full record on ClinicalTrials.gov
Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.